↓ Skip to main content

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

Overview of attention for article published in BMC Cancer, June 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
54 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies
Published in
BMC Cancer, June 2020
DOI 10.1186/s12885-020-07008-8
Pubmed ID
Authors

Cornelis M. van Tilburg, Ruth Witt, Melanie Heiss, Kristian W. Pajtler, Christoph Plass, Isabel Poschke, Michael Platten, Inga Harting, Oliver Sedlaczek, Angelika Freitag, David Meyrath, Lenka Taylor, Gnana Prakash Balasubramanian, Natalie Jäger, Elke Pfaff, Barbara C. Jones, Till Milde, Stefan M. Pfister, David T. W. Jones, Annette Kopp-Schneider, Olaf Witt

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 15%
Researcher 7 13%
Student > Postgraduate 4 7%
Student > Ph. D. Student 4 7%
Lecturer 3 6%
Other 7 13%
Unknown 21 39%
Readers by discipline Count As %
Medicine and Dentistry 16 30%
Biochemistry, Genetics and Molecular Biology 4 7%
Nursing and Health Professions 3 6%
Psychology 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 7 13%
Unknown 21 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2021.
All research outputs
#6,551,016
of 23,213,531 outputs
Outputs from BMC Cancer
#1,682
of 8,418 outputs
Outputs of similar age
#142,606
of 398,014 outputs
Outputs of similar age from BMC Cancer
#50
of 178 outputs
Altmetric has tracked 23,213,531 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 8,418 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,014 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 178 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.